# US 2009/0155251 A1 · Polypeptide compounds for inhibiting angiogenesis and tumor growth

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0155251 A1
- Document ID: US20090155251A1
- Status: Published application
- Kind: A1
- Application number: 12/156,553
- Filed: 2008-06-02
- Published: 2009-06-18
- Earliest claimed: 2003-03-12
- Assignees: VasGene Therapeutics, Inc.
- Inventors: Valery Krasnoperov; Sergey Zozulya; Nathalie Kertesz; Ramachandra Reddy; Parkash Gill
- Web page: https://patentgrep.com/patent/US20090155251A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 35/00: Antineoplastic agents
- C07K 14/715: for cytokines; for lymphokines; for interferons
- C07K 16/30: from tumour cells
- C12N 15/1138: {against receptors or cell surface proteins}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

In certain embodiments, this present invention provides polypeptide compositions, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.

## Claims

### Claim 1

An isolated antibody or antigen binding portion thereof that binds to an epitope situated in the extracellular portion of EphB4 and inhibits an EphB4 activity.

### Claim 2 (depends on 1)

The isolated antibody or antigen binding portion thereof of claim 1, wherein the antibody or antigen binding portion thereof binds to an epitope situated within amino acids 16-198 of the EphB4 sequence of FIG. 1.

### Claim 3 (depends on 2)

The isolated antibody or antigen binding portion thereof of claim 2, wherein the antibody or antigen binding portion thereof inhibits the binding of EphB4 to the extracellular portion of EphrinB2.

### Claim 4 (depends on 1)

The isolated antibody or antigen binding portion thereof of claim 1, wherein the antibody or antigen binding portion thereof binds to an epitope situated within amino acids 327-427 or 428-537 of the EphB4 sequence of FIG. 1.

### Claim 5 (depends on 4)

The isolated antibody or antigen binding portion thereof of claim 4, wherein the antibody or antigen binding portion thereof inhibits the formation of EphB4 dimers or multimers.

### Claim 6 (depends on 3)

The isolated antibody or antigen binding portion thereof of claim 3, wherein the antibody or antigen binding portion thereof binds to the first fibronectin-like domain (FND1) of EphB4.

### Claim 7 (depends on 3)

The isolated antibody or antigen binding portion thereof of claim 3, wherein the antibody or antigen binding portion thereof binds to the second fibronectin-like domain (FND2) of EphB4.

### Claim 8 (depends on 1)

The isolated antibody or antigen binding portion thereof of claim 1, wherein the antibody or antigen binding portion thereof inhibits the EphrinB2-stimulated autophosphorylation of EphB4.

### Claim 9 (depends on 1)

The isolated antibody or antigen binding portion thereof of claim 1, wherein the antibody or antigen binding portion thereof inhibits the formation of tubes by cultured endothelial cells.

### Claim 10 (depends on 1)

The isolated antibody or antigen binding portion thereof of claim 1, wherein the antibody or antigen binding portion thereof inhibits the vascularization of a tissue in vivo.

### Claim 11 (depends on 10)

The isolated antibody or antigen binding portion thereof of claim 10, wherein the antibody or antigen binding portion thereof inhibits the vascularization of tissue implanted in the cornea of an animal.

### Claim 12 (depends on 10)

The isolated antibody or antigen binding portion thereof of claim 10, wherein the antibody or antigen binding portion thereof inhibits the vascularization of a Matrigel tissue plug implanted in an animal.

### Claim 13 (depends on 1)

The isolated antibody or antigen binding portion thereof of claim 1, wherein the antibody or antigen binding portion thereof decreases the growth of a human tumor xenograft in a mouse.

### Claim 14 (depends on 2)

The isolated antibody of claim 2, wherein the antibody is selected from the group consisting of antibodies denoted herein as No. 001, No. 023, No. 035, and No. 079.

### Claim 15 (depends on 2)

The isolated antibody of claim 2, wherein the antibody is a humanized version of an antibody selected from the group consisting of antibodies denoted herein as No. 001, No. 023, No. 035, and No. 079.

### Claim 16 (depends on 2)

The isolated antibody or antigen binding portion thereof of claim 2, wherein the antibody or antigen binding portion thereof comprises at least one CDR portion derived from an antibody selected from the group consisting of antibodies denoted herein as No. 001, No. 023, No. 035, and No. 079.

### Claim 17 (depends on 4)

The isolated antibody of claim 4, wherein the antibody is selected from the group consisting of antibodies denoted herein as No. 047, No. 057, No. 85H, No. 098, and No.

### Claim 18 (depends on 4)

The isolated antibody of claim 4, wherein the antibody is a humanized version of an antibody selected from the group consisting of antibodies denoted herein as No. 001, No. 023, No. 035, and No. 079.

### Claim 19 (depends on 4)

The isolated antibody or antigen binding portion thereof of claim 4, wherein the antibody or antigen binding portion thereof comprises at least one CDR portion derived from an antibody selected from the group consisting of antibodies denoted herein as No. 001, No. 023, No. 035, and No. 079.

### Claim 20 (depends on 1)

The antibody of claim 1, wherein the antibody is a monoclonal antibody.

### Claim 21 (depends on 20)

The antibody of claim 20, wherein the monoclonal antibody is clinically acceptable for administration to a human.

### Claim 22 (depends on 1)

A hybridoma that produces an antibody of claim 1.

### Claim 23

A hybridoma that produces an antibody selected from the group consisting of antibodies denoted herein as No. 001, No. 023, No. 035, No. 079, No. 047, No. 057, No. 85H, No. 098, and No. 138.

### Claim at position 24

24-29. (canceled)

### Claim 30 (depends on 1)

A pharmaceutical preparation comprising the isolated antibody or antigen binding portion thereof of claim 1.

### Claim at position 26

31-32. (canceled)

### Claim 33

An isolated antibody or antigen binding portion thereof that binds to an epitope situated within amino acids 327-427 or 428-537 of the EphB4 sequence of FIG. 1 and stimulates EphB4 kinase activity.

### Claim 34 (depends on 33)

The isolated antibody or antigen binding portion thereof of claim 33, wherein the antibody binds to the first fibronectin-like domain (FND1) of EphB4.

### Claim 35 (depends on 34)

The isolated antibody of claim 34, wherein the antibody binds to the second fibronectin-like domain (FND2) of EphB4.

### Claim 36 (depends on 33)

The isolated antibody of claim 33, wherein the antibody is selected from the group consisting of antibodies denoted herein as No. 85L, No. 091, No. 121, and No. 131.

### Claim 37 (depends on 33)

The isolated antibody of claim 33, wherein the antibody is a humanized version of an antibody selected from the group consisting of antibodies denoted herein as No. 85L, No. 091, No. 121, and No. 131.

### Claim 38 (depends on 33)

The isolated antibody or antigen binding portion thereof of claim 33, wherein the antibody or antigen binding portion thereof comprises at least one CDR portion derived from an antibody selected from the group consisting of antibodies denoted herein as No. 85L, No. 091, No. 121, and No. 131.

### Claim 39 (depends on 33)

The antibody of claim 33, wherein the monoclonal antibody is clinically acceptable for administration to a human.

### Claim 40 (depends on 33)

A hybridoma that produces an antibody of claim 33.

### Claim 41

A hybridoma that produces an antibody selected from the group consisting of antibodies denoted herein as No. 001, No. 023, No. 035, No. 079, No. 047, No. 057, No. 85H, No. 098, and No. 138.

### Claim at position 36

42-47. (canceled)

### Claim 48 (depends on 33)

A pharmaceutical preparation comprising the isolated antibody or antigen binding portion thereof of claim 33.

### Claim at position 38

49-50. (canceled)

### Claim 51

An antibody that specifically binds to an epitope situated in the extracellular portion of EphB4, wherein the antibody is selected from the group consisting of Nos. 1, 23, 35, 47, 57, 79, 85L, 85H, 91, 98, 121, 131, and 138.

### Claim 52 (depends on 1, 33)

An isolated antibody or antigen binding portion thereof of claim 1 or claim 33, wherein the isolated antibody or antigen binding portion thereof is covalently linked to an additional functional moiety.

### Claim 53 (depends on 52)

The isolated antibody or antigen binding portion thereof of claim 52, wherein the additional functional moiety is a label.

### Claim 54 (depends on 53)

The isolated antibody or antigen binding portion thereof of claim 53, wherein the label is suitable for detection by a method selected from the group consisting of: fluorescence detection methods, positron emission tomography detection methods and nuclear magnetic resonance detection methods.

### Claim 55 (depends on 54)

The isolated antibody or antigen binding portion thereof of claim 54, wherein the label is selected from the group consisting of: a fluorescent label, a radioactive label, and a label having a distinctive nuclear magnetic resonance signature.

### Claim 56 (depends on 52)

The isolated antibody or antigen binding portion thereof of claim 52, wherein the additional functional moiety confers increased serum half-life on the antibody or antigen binding portion thereof.

### Claim 57 (depends on 56)

The isolated antibody or antigen binding portion thereof of claim 56, wherein the additional functional moiety comprises a polyethylene glycol (PEG) moiety.
